Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
Sara Moufarrij, Aneil Srivastava, Stephanie Gomez, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Brandie C. Taylor, Justin M. Balko
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 150
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Lourdes Hontecillas‐Prieto, Rocío Flores-Campos, Andrew Silver, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 142
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Jing Yang, Jin Xu, Wei Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 140
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Xiangyu Wu, Tianhang Li, Rui Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 65
Epigenetic regulation in cancer
Minzhi Gu, Bo Ren, Yuan Fang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 17
The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications
Daoqi Zhu, Siying Zeng, Chao Su, et al.
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 16
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Aleksandra Majchrzak‐Celińska, Anna Warych, Mikołaj Szoszkiewicz
Genes (2021) Vol. 12, Iss. 2, pp. 208-208
Open Access | Times Cited: 88
Ovarian cancer: epigenetics, drug resistance, and progression
Weiwei Xie, Huizhen Sun, Xiaoduan Li, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 64
HDAC6: A unique HDAC family member as a cancer target
Sumeet Kaur, Prerna Rajoria, Madhu Chopra
Cellular Oncology (2022) Vol. 45, Iss. 5, pp. 779-829
Closed Access | Times Cited: 55
Tumor immune evasion through loss of MHC class-I antigen presentation
Gülce Sarı, Kenneth L. Rock
Current Opinion in Immunology (2023) Vol. 83, pp. 102329-102329
Open Access | Times Cited: 27
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy
Guohao Wang, Jie Yan, Hao Tian, et al.
Advanced Materials (2024) Vol. 36, Iss. 19
Open Access | Times Cited: 10
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Daniela Matei, Kenneth P. Nephew
Cancer Research (2020) Vol. 80, Iss. 18, pp. 3775-3785
Open Access | Times Cited: 62
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update
Priya Mondal, Jagadish Natesh, Dhanamjai Penta, et al.
Seminars in Cancer Biology (2020) Vol. 83, pp. 503-522
Closed Access | Times Cited: 60
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside
Federica Sarno, Giuditta Benincasa, Markus List, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 51
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
Siddhartha Das Pramanik, Amit Kumar Halder, Ushmita Mukherjee, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 30
Curriculum vitae of HDAC6 in solid tumors
Yi‐Chao Zheng, Huiqin Kang, Bo Wang, et al.
International Journal of Biological Macromolecules (2023) Vol. 230, pp. 123219-123219
Closed Access | Times Cited: 19
Challenges and solutions for therapeuticTCR‐based agents
Manish Malviya, Zita E. H. Aretz, Zaki Molvi, et al.
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 58-82
Closed Access | Times Cited: 16
HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy
Yuqing Wen, Shuyu Ye, Zhengshuo Li, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 1
Open Access | Times Cited: 7
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Zhicheng Gu, Shuxian Lin, Junhui Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116571-116571
Closed Access | Times Cited: 6
Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer
Stephanie Gomez, Olivia L. Cox, Reddick R. Walker, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 11, pp. e004974-e004974
Open Access | Times Cited: 23
Predicting drug response from single-cell expression profiles of tumours
Simona Pellecchia, Gaetano Viscido, Melania Franchini, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
Jie Peng, Fei Xie, Pengxia Qin, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106622-106622
Open Access | Times Cited: 13
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids
Dexter Kai Hao Thng, Lissa Hooi, Bei En Siew, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies
Laurence Haddadin, Xueqin Sun
Cells (2025) Vol. 14, Iss. 7, pp. 538-538
Open Access
Page 1 - Next Page

Scroll to top